Remove Biotechnology Remove Life Sciences Remove Pharmaceuticals Remove Regulations
article thumbnail

Don’t Be Too Alarmed by the New SCOTUS Antibody Ruling

Bill Of Health

Attorney Gene Quinn offers the most dramatic interpretation, calling the Supreme Court’s embrace of full scope enablement in Amgen “a cataclysmic shift in the law of enablement,” not just for antibodies but for “the life sciences community and beyond.” Amgen’s significance has often been overstated. It was formally repealed in 2018.)

article thumbnail

Hong Kong Exchange: Nurturing China’s Biotech Valley

Health Advances

Investors in Hong Kong who are closer to China can better understand the equity story of Chinese biotechnology companies. Following Hong Kong’s steps, Shanghai’s Science and Technology Innovation Market (STAR) changed its criteria to allow pre-revenue biotechs to list in May. explains Chen.